Little reminder gents (and ladies) of the trial:
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372643
Secondary outcomes are function and pain measurements including VAS scores. Lets not forget on a 0-10 pain score, ATI saw improvements from 5.94 at the initial assessment to 0.76 at 12 months (P < .001) in its lateral epicondylitis study. The best measure of the success was for me grip strength scores improving over the 12-month follow-up from 20.17 kg [baseline] to 37.38 kg; P < .001):
https://journals.sagepub.com/doi/abs/10.1177/0363546513504285
Pretty compelling stuff for those who've ever endured tendinosis. I am very excited by these forthcoming results and only wish they'd including more secondary data - but too many studies get loaded down with multiplicity criticisms, so OCC have kept it simple with preferred orthcopedic composite measures.
- Forums
- ASX - By Stock
- OCC
- J&J Partnership
J&J Partnership, page-306
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
|
|||||
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $80.59M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 38.5¢ | $17.64K | 45.67K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 23269 | 38.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 25000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 23269 | 0.385 |
4 | 20914 | 0.380 |
5 | 81340 | 0.375 |
10 | 112676 | 0.370 |
4 | 80622 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 25000 | 2 |
0.400 | 290626 | 12 |
0.405 | 65143 | 3 |
0.410 | 157677 | 7 |
0.415 | 3200 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online